First-in-Class PPMS Indication Fueling Much of the Adoption of Genentech’s Ocrevus, but Insurance Coverage Issues Could be a Looming Stumbling Block

As previously predicted, Ocrevus trial and share has increased significantly, positioning the new market entrant as second only to Biogen's Tysabri in the mAb DMT class, according to the most recent quarterly update by Spherix Global Insights Download Report Overview EXTON, Pa., Sept. 19, 2017 /PRNewswire/ — Four months post-launch, keeping pace with neurologists' previous [...]

First-in-Class PPMS Indication Fueling Much of the Adoption of Genentech’s Ocrevus, but Insurance Coverage Issues Could be a Looming Stumbling Block 2017-09-19T15:50:49+00:00

Early Launch Metrics for Janssen’s Tremfya May Lag Those of Lilly’s Taltz at a Similar Post-Launch Period, but Signs Indicate the New IL-23 Inhibitor is Poised to Set a New Bar for Efficacy in Skin

According to Spherix Global Insight's latest quarterly release of RealTime Dynamix™: Psoriasis, dermatologists are feeling increasingly overwhelmed with the sheer number of new biologic entrants recently approved in the US. Download Report Overview EXTON, Pa., Sept. 14, 2017 /PRNewswire/ -- At just over one-month post launch, more dermatologists were aware of Taltz's approval compared to [...]

Early Launch Metrics for Janssen’s Tremfya May Lag Those of Lilly’s Taltz at a Similar Post-Launch Period, but Signs Indicate the New IL-23 Inhibitor is Poised to Set a New Bar for Efficacy in Skin 2017-09-15T14:51:36+00:00

US Gastroenterologists May Thwart Uptake of New Biosimilars, Such as Pfizer’s Inflectra and Merck/Samsung Bioepis’ Renflexis, by Choosing an Alternative TNF-Inhibitor, Such as AbbVie’s Humira

Despite Remicade's status as the go-to agent in ulcerative colitis (UC), the introduction and adoption of the biosimilar Inflectra appears to be having an impact on the brand, with share for Janssen's branded infliximab significantly down compared to the same period last year, according to a recent report from Spherix Global Insights Download Report Overview [...]

US Gastroenterologists May Thwart Uptake of New Biosimilars, Such as Pfizer’s Inflectra and Merck/Samsung Bioepis’ Renflexis, by Choosing an Alternative TNF-Inhibitor, Such as AbbVie’s Humira 2017-08-30T16:01:33+00:00

Uptake of Sanofi/Regeneron’s Dupixent for Atopic Dermatitis Strong, but Sales Representative Contact Rates Leave Something to be Desired

At roughly four months post-launch, the Dupixent patient and user base has experienced substantial growth, though nearly one-third of US dermatologists have yet to see a sales representative according to recent report from Spherix Global Insights Download Report Overview EXTON, Pa., Aug. 21, 2017 /PRNewswire/ -- According to the Q3 update of RealTime Dynamix™: Atopic [...]

Uptake of Sanofi/Regeneron’s Dupixent for Atopic Dermatitis Strong, but Sales Representative Contact Rates Leave Something to be Desired 2017-08-30T16:02:00+00:00

Novartis’ Cosentyx Beginning to Plateau in Psoriatic Arthritis, as US Rheumatologists Prepare for an Influx of Non-TNF Agents, Such as BMS’ Orencia, Pfizer’s Xeljanz, and Lilly’s IL-17, Taltz

Despite an increasing user base, Cosentyx share has remained unchanged over the past six months, according to recently released data from Spherix Global Insights Download Report Overview EXTON, Pa., Aug. 15, 2017 /PRNewswire/ -- In the most recent quarterly update of RealTime Dynamix™ Psoriatic Arthritis, a growing population of US rheumatologists (n=101) are reporting use [...]

Novartis’ Cosentyx Beginning to Plateau in Psoriatic Arthritis, as US Rheumatologists Prepare for an Influx of Non-TNF Agents, Such as BMS’ Orencia, Pfizer’s Xeljanz, and Lilly’s IL-17, Taltz 2017-08-30T16:02:28+00:00